PTPRC and neoplasm: IHC of CD45+ leukocytes demonstrated that these PRC2-loss tumors had low levels of tumor immune infiltrates that were comparable to those of PRC2-loss MPNSTs (Supplemental Figure 1F and Figure 1C).